Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2.
OBJECTIVE
The purpose of the present study was to identify the clinical and pathologic features of ovarian cancers in patients who have a family history of breast or ovarian cancer but who do not have a mutation in the BRCA1 or BRCA2 gene.


METHODS
303 patients with ovarian cancer were reviewed for clinical features and for cancer family histories. After the exclusion of 51 patients known to carry BRCA1 or BRCA2 mutations, 24 patients with familial cancer were compared with 228 patients with non-familial cancer.


RESULTS
Patients with familial cancer were more likely to have grade 2 tumors, Stage II disease and to present between ages 51 and 60 than were non-familial controls. Ten of 24 patients in the familial group presented between ages 51 and 60 with a grade 2 tumor compared to 3.0 expected (p = 0.001).


CONCLUSIONS
Families of women who present with grade 2 ovarian cancer between the ages of 51 and 60 may have an unidentified ovarian cancer susceptibility gene.
Menkiszak
J
J
Clinic of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
Gronwald
J
J
Górski
B
B
Byrski
T
T
Huzarski
T
T
Jakubowska
A
A
Foszczyńska-Kłoda
M
M
Brzosko
M
M
Fliciński
J
J
Rzepka-Górska
I
I
Narod
S A
SA
Lubiński
J
J
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D011044:Poland / Q000453:epidemiology